廣州創(chuàng)侖違禁品檢測(cè)試紙

                         廣州健侖生物科技有限公司                     

獨(dú)立包裝：BZO-BAR-COC--THC -MET--OPI-OXY-MDMA-PCP- AMP-XTC-MTD 或聯(lián)檢

MOB： 楊   ：  

本品采用卨度特異性的抗體抗原反應(yīng)及免疫色譜分析技術(shù)， 通過(guò)單克隆抗體競(jìng)爭(zhēng)結(jié)合咖啡音偶聯(lián)物和尿液中可能含有的咖啡音的原理。試劑盒含有被亊先固定于膜上測(cè)試區(qū)(T)的咖啡音偶聯(lián)物和被膠體金標(biāo)記的抗咖啡音單克降抗體。測(cè)試時(shí)，尿樣滴入試劑盒(S)孔內(nèi)，尿樣隨之在毛細(xì)效應(yīng) 下向上層析。如咖啡音在尿樣中濃度低于6Ug/ml時(shí)，膠體金抗體不能與咖啡音全部結(jié)合。這樣,膠體金抗體在層析過(guò)程中會(huì)被固定在膜上的咖啡音偶聯(lián)物結(jié)合,在測(cè)試區(qū)內(nèi)(T)會(huì)出現(xiàn)一條紫紅色條帶。如果咖啡音在尿樣中濃度高于6ug/ml時(shí)，膠體金抗體與咖啡音全部結(jié)合,從而在測(cè)試區(qū)內(nèi)(T)因?yàn)楦?jìng)爭(zhēng)反應(yīng)不會(huì)與 咖啡音偶朕物結(jié)合而不出現(xiàn)紫紅色條帶。陰性尿樣在檢測(cè)過(guò)程中由于缺少抗體抗原競(jìng)爭(zhēng)反應(yīng),將會(huì)在測(cè)試區(qū)內(nèi)（T)出現(xiàn)紫紅色 條帶。無(wú)論咖啡音是否存在于尿樣中，一條紫紅色條帶都會(huì)出現(xiàn)在質(zhì)控區(qū)內(nèi)（C)。質(zhì)控區(qū)內(nèi)（C)所顯現(xiàn)的紫紅色條帶是判定是否有足夠尿樣,層析過(guò)程是否正常的標(biāo)準(zhǔn)，同時(shí)也作為試劑的內(nèi)控標(biāo)準(zhǔn)。

廣州創(chuàng)侖違禁品檢測(cè)試紙

陽(yáng)性（+):僅質(zhì)控區(qū)（C)出現(xiàn)一條紫紅色條帶，在測(cè)試區(qū) (T)內(nèi)無(wú)紫紅色條帶出現(xiàn)。陽(yáng)性結(jié)果表明：尿液中的咖啡音濃度在閾 值(6ug/ml)以上。

陰性（-):兩條紫紅色條帶出現(xiàn)。一條位于測(cè)試區(qū)（T)內(nèi)，另一 條位于質(zhì)控區(qū)內(nèi)（C)。陰性結(jié)果表明：尿液中的咖啡音濃度在閾 值(6ug/ml)以下,

無(wú)效：質(zhì)控區(qū)（C)未出現(xiàn)紫紅色條帶，表明不正確的操作過(guò)程或試劑盒已變質(zhì)損壞。在任何情況下，應(yīng)重新測(cè)試。如果問(wèn)題仍 然存在，應(yīng)立即停止使用此批號(hào)產(chǎn)品，并與當(dāng)?shù)毓?yīng)商。

注意：測(cè)試區(qū)（T)內(nèi)的紫紅色條帶可顯現(xiàn)出顏色深淺的現(xiàn)象。 但是，在規(guī)定的觀察時(shí)間內(nèi)，不論該色帶顏色深淺，即使只有非 常弱的色帶也應(yīng)判定為陰性結(jié)果。

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【市場(chǎng)部】       楊永漢
【】 
【騰訊 】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號(hào)二期2幢101-103室

以兔和猴作為實(shí)驗(yàn)動(dòng)物的研究中獲得的疫苗保護(hù)性抗體水平，用來(lái)預(yù)測(cè)在人類的免疫反應(yīng)水平。當(dāng)吸入性炭疽動(dòng)物模型有70%的保護(hù)率時(shí)，被認(rèn)為是一個(gè)合理的保護(hù)水平，而且在人類可能也會(huì)如此。
利用兔子評(píng)價(jià)了BioThrax用于暴露后注射結(jié)合抗生素治療以增加存活率的效果。結(jié)果，同時(shí)接受抗生素和BioThrax治療的兔子存活率在 70-100%之間，具體的存活率與疫苗的使用劑量和使用途徑相關(guān)。而僅使用抗生素治療的兔子存活率僅有44%和23%。
BioThrax的不良反應(yīng)主要表現(xiàn)為注射部位局部的不良反應(yīng)，如注射部位發(fā)藥、壓痛、疼痛、腫脹，以及注射的手臂運(yùn)動(dòng)受限。zui細(xì)菌見(jiàn)的全身性不良反應(yīng)是肌肉酸痛、頭痛和疲勞。研究人員在從中國(guó)不同地方的人和豬體內(nèi)采集的樣本（包括具有傳染性的細(xì)菌樣本）中，發(fā)現(xiàn)了一種能對(duì)*抗生素產(chǎn)生強(qiáng)耐藥性的新基因。
路透社11月18日?qǐng)?bào)道稱，科學(xué)家稱這一發(fā)現(xiàn)“令人擔(dān)憂”，并呼吁緊急限制多粘菌素的使用。多粘菌素是一種包含藥用粘菌素并在畜牧業(yè)中廣泛使用的抗生素。英國(guó)伯明翰大學(xué)微生物學(xué)教授勞拉?皮多克說(shuō)：“所有多粘菌素的使用都必須盡快降至zui低限度，并停止一切不必要的使用。”
中國(guó)華南農(nóng)業(yè)大學(xué)劉健華研究團(tuán)隊(duì)在英國(guó)《柳葉刀?傳染細(xì)菌》雜志上發(fā)表了他們的研究成果。他們?cè)谫|(zhì)粒上發(fā)現(xiàn)了這種名為mcr-1的基因。質(zhì)粒是容易被復(fù)制并在不同細(xì)菌間轉(zhuǎn)移的可移動(dòng)DNA元件。他們說(shuō)，這說(shuō)明該基因具有在細(xì)菌種群間傳播和突變的“令人擔(dān)憂的潛力”。
這個(gè)研究團(tuán)隊(duì)已發(fā)現(xiàn)了mcr-1基因在細(xì)菌見(jiàn)細(xì)菌之間轉(zhuǎn)移的證據(jù)，比如在大腸桿菌（可引起尿道及其他類型感染）與肺炎克雷伯菌（引發(fā)肺炎及其他感染）之間轉(zhuǎn)移。這說(shuō)明“從多耐藥性向泛耐藥性的發(fā)展是不可避免的”。“雖然目前僅限于中國(guó)，但mcr-1很可能像其他耐藥性基因一樣……，很快傳播到*。”
日益?zhèn)鞑サ膍cr-1耐藥性基因被發(fā)現(xiàn)，令人想起2010年另一種所謂“超級(jí)細(xì)菌”基因NDM-1被發(fā)現(xiàn)的新聞。那種基因出現(xiàn)在印度，很快傳播至*。
皮多克等人說(shuō)，現(xiàn)在有必要建立mcr-1耐藥性基因監(jiān)控體系，努力阻止耐多粘菌素細(xì)菌的傳播。
中國(guó)是*zui大的農(nóng)用和獸用粘菌素生產(chǎn)國(guó)和使用國(guó)之一。

企業(yè)文化

Vaccine levels of protective antibodies obtained from studies in rabbits and monkeys as experimental animals were used to predict the level of immune response in humans. When the animal model of inhalation anthrax has a 70% protection rate, it is considered a reasonable level of protection and may also be so in humans.
Rabbits were used to evaluate the effect of BioThrax for post-exposure injection combined with antibiotic therapy to increase survival. As a result, the survival rate of rabbits treated with both antibiotics and BioThrax was between 70-100%. The specific survival rate was related to the dosage and route of administration of the vaccine. Survival rates of rabbits treated with antibiotics were only 44% and 23%, respectively.
Adverse reactions to BioThrax are mainly local adverse reactions at the injection site, such as injection site pain, tenderness, pain, swelling, and limited arm motility during injection. The most common systemic side effects seen are muscle aches, headaches, and fatigue. Researchers have found a new gene that is highly resistant to the ultimate antibiotic in samples collected from humans and pigs in various parts of China, including infectious bacterial specimens.
Reuters reported on November 18 that scientists found the discovery "troubling" and called for an urgent limit on the use of polymyxins. Polymyxin is an antibiotic that includes medicinal colistin and is widely used in animal husbandry. Laura Picode, a professor of microbiology at the University of Birmingham in the United Kingdom, said: "All polymyxins must be used as quickly as possible and all unnecessary use is stopped."
Liu Jianhua, a research team at South China Agricultural University in China, published their research results in the British journal Lancet Infectious Bacteria. They found the gene called mcr-1 on the plasmid. Plasmids are removable DNA elements that are easily replicated and transferred between different bacteria. They say this shows "the worrying potential" that the gene has the ability to spread and mutate between bacterial populations.
The team has found evidence of the transfer of the mcr-1 gene from bacteria to bacteria, such as between E. coli, which causes infections of the urethra and other types, and Klebsiella pneumoniae, which causes pneumonia and other infections. This shows that "the development from multi-drug resistance to pan-drug resistance is inevitable." "Although currently limited to China, mcr-1 is likely to be the same as other resistance genes ... and spread to the world quickly."
The growing spread of the mcr-1 resistance gene was discovered, reminiscent of news that another 2010 so-called "superbug" gene NDM-1 was discovered. That gene appeared in India and soon spread to the world.
Pidok et al say that there is now a need to establish a global mcr-1 drug resistance gene surveillance system in an effort to stop the spread of polymyxin-resistant bacteria.
China is one of the largest producers and consumers of colistin for agriculture and veterinary in the world.